Journal Article

NIR-laser-triggered gadolinium-doped carbon dots for magnetic resonance imaging, drug delivery and combined photothermal chemotherapy for triple negative breast cancer

Huang, Dongping, Liu, Li, Chen, Dong, Chen, Xing, Li, Qiuying, Huang, Gang, Jiang, Qunjiao, Du, Qishi, Cao, Yi, Yang, Xiaobo, Pei, Renjun

2021

Overview

Background Owing to high genetic diversities of tumor cells and low response rate of standard chemotherapy, patients with triple negative breast cancer (TNBC) have short progression-free survivals and poor outcomes, which need to explore an effective approach to improve therapeutic efficacy. Methods Novel gadolinium doped carbon dots (Gd@CDs) have been designed and prepared through hydrothermal method with 3,4-dihydroxyhydrocinnamic acid, 2,2′-(ethylenedioxy)bis(ethylamine) and gadolinium chloride. The synthesized nanostructures were characterized. Taking advantage of good biocompatibility of Gd@CDs, a nanoplatform based on Gd@CDs has been developed to co-deliver chemotherapy drug doxorubicin hydrochloride (Dox) and a near-infrared (NIR) photothermal agent, IR825 for magnetic resonance imaging (MRI) guided photothermal chemotherapy for TNBC. Results The as-synthesized Dox@IR825@Gd@CDs displayed favorable MRI ability in vivo . Upon NIR laser irradiation, Dox@IR825@Gd@CDs could convert the NIR light to heat and efficiently inhibit tumor growth through photothermal chemotherapy in vitro and in vivo. Additionally, the impact of photothermal chemotherapy on the murine motor coordination was assessed by rotarod test. Dox@IR825@Gd@CDs presented low toxicity and high photothermal chemotherapy efficiency. Conclusion A noble theranostic nanoplatform (Dox@IR825@Gd@CDs) was developed that could be tailored to achieve loading of Dox and IR825, intracellular delivery, favorable MRI, excellent combination therapy with photothermal therapy and chemotherapy to enhance therapeutic effect against TNBC cells. This study will provide a promising strategy for the development of Gd-based nanomaterials for MRI and combinational therapy for TNBC. Graphic abstract

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Animals / Biocompatibility / Biotechnology / Breast cancer / Cancer / Cancer therapies / Carbon / Carbon - chemistry / Carbon dots / Care and treatment / Cell Line, Tumor / Chemistry / Chemistry and Materials Science / Chemotherapy / Combined Modality Therapy / Complications and side effects / Doxorubicin / Drug Carriers - chemistry / Drug delivery / Drug delivery systems / Drug Delivery Systems - methods / Drug Therapy - methods / Drugs / Efficiency / Evaluation / Female / Fourier transforms / Gadolinium / Gadolinium - chemistry / Genetic aspects / Genetic diversity / Hemodialysis / Humans / In vivo methods and tests / Infrared Rays / Irradiation / Laboratory animals / Lasers / Lymphocytes / Magnetic resonance imaging / Magnetic Resonance Imaging - methods / Medical imaging / Metastasis / Mice / Mice, Inbred BALB C / Mice, Nude / Molecular Medicine / Nanomaterials / Nanoparticles / Nanoparticles - chemistry / Nanostructures - chemistry / Nanotechnology / Near infrared radiation / NMR / Nuclear magnetic resonance / Patient outcomes / Permeability / Photochemotherapy / Phototherapy - methods / Photothermal chemotherapy / Resonance / Synthesis / Toxicity / Triple negative breast cancer therapy / Triple Negative Breast Neoplasms - drug therapy / Triple Negative Breast Neoplasms - radiotherapy / Tumor cells / Tumors / Vehicles / Xenograft Model Antitumor Assays